Accelerant Holdings (ARX)
| Market Cap | 2.93B |
| Revenue (ttm) | 856.30M +52.4% |
| Net Income | -1.43B |
| EPS | -7.49 |
| Shares Out | 222.16M |
| PE Ratio | n/a |
| Forward PE | 19.38 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 883,343 |
| Open | 13.45 |
| Previous Close | 13.56 |
| Day's Range | 13.10 - 13.60 |
| 52-Week Range | 9.18 - 31.18 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 19.00 (+43.94%) |
| Earnings Date | May 13, 2026 |
About ARX
Accelerant Holdings, together with its subsidiaries, operates a data-driven risk exchange that connects selected specialty insurance underwriters with risk capital partners. The company operates through Exchange Services, MGA Operations, and Underwriting segments. The Exchange Services segment consists of risk exchange, its operating platform that incorporates various technology, data ingestion, and agency operations that serve the needs of its members and risk capital partners. Its Risk capital partners write premiums directly through the Risk... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for ARX stock is "Buy." The 12-month stock price target is $19.0, which is an increase of 43.94% from the latest price.
News
Accelerant Announces Date of First Quarter 2026 Financial Results and Conference Call
ATLANTA--(BUSINESS WIRE)--Accelerant Holdings (NYSE: ARX), the data-driven risk exchange platform transforming the specialty insurance marketplace through the Accelerant Risk Exchange, today announced...
Unbuzzd Wellness Appoints Richard Buzbuzian as CEO to Lead Nationwide Commercialization of Innovative, Clinically Validated Hangover Remedy and Alcohol Metabolism Accelerant
Vancouver, British Columbia--(Newsfile Corp. - April 22, 2026) - Unbuzzd Wellness Inc. (the "Company" or "Unbuzzd"), the company behind unbuzzdTM ("unbuzzd") — the scientifically-proven and game-chang...
Accelerant price target lowered to $17 from $20 at Citizens
Citizens analyst Matthew Carletti lowered the firm’s price target on Accelerant (ARX) to $17 from $20 and keeps an Outperform rating on the shares. The firm expects Q1 results to
Accelerant price target raised to $30 from $28 at BMO Capital
BMO Capital analyst Randy Ollenberger raised the firm’s price target on Accelerant (ARX) to $30 from $28 and keeps an Outperform rating on the shares as part of a broader
Accelerant price target lowered to $15 from $16 at Morgan Stanley
Morgan Stanley analyst Bob Huang lowered the firm’s price target on Accelerant (ARX) to $15 from $16 and keeps an Equal Weight rating on the shares. The firm adjusted target
Accelerant Completes CFO Transition
ATLANTA--(BUSINESS WIRE)--Accelerant appointed Linda S. Huber as Chief Financial Officer following the previously announced CFO transition.
Accelerant price target lowered to $30 from $36 at TD Cowen
TD Cowen lowered the firm’s price target on Accelerant (ARX) to $30 from $36 and keeps a Buy rating on the shares. The firm updated its model following Q4 results.
Accelerant price target lowered to $16 from $17 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Accelerant (ARX) to $16 from $17 and keeps an Equal Weight rating on the shares. The firm updated its model to incorporate
Accelerant price target lowered to $16.50 from $22.50 at BMO Capital
BMO Capital analyst Michael Zaremski lowered the firm’s price target on Accelerant (ARX) to $16.50 from $22.50 and keeps an Outperform rating on the shares. The firm cites lower benchmark
Accelerant upgraded to Overweight from Equal Weight at Wells Fargo
Wells Fargo upgraded Accelerant (ARX) to Overweight from Equal Weight with a price target of $15, down from $17. The stock fell on what was a good quarter and outlook
Accelerant Holdings Earnings Call Transcript: Q4 2025
Q4 and full-year 2025 results exceeded expectations, with strong premium growth, expanding margins, and robust free cash flow. AI-driven underwriting and a growing member base support continued outperformance, while guidance for 2026 points to further growth and a shift toward fee-based revenue.
Accelerant board authorizes up to $200M share repurchase program
On March 18, 2026, Accelerant’s (ARX) Board of Directors authorized a share repurchase program to purchase up to $200M of the Company’s Class A common shares, effective through December 31,
Accelerant sees growth in adjusted EBITDA in 2026
“Our 2026 outlook reflects continued momentum across the Accelerant (ARX) Risk Exchange, with Exchange Written Premium expected to grow more than 20% year-over-year as third-party capital participatio...
Accelerant CFO Jay Green to resign, Linda Huber named next CFO
Accelerant (ARX) announced that Jay Green has notified the Board of Directors that he will resign from his role of Chief Financial Officer to pursue personal interests, with effect from
Accelerant Announces Fourth Quarter and Full Year 2025 Results
ATLANTA--(BUSINESS WIRE)--Accelerant Holdings (NYSE: ARX) today announced financial results for the fourth quarter and full year ended December 31, 2025.
Accelerant Announces Unaudited Preliminary Fourth Quarter and Full Year 2025 Financial Results
ATLANTA--(BUSINESS WIRE)--Accelerant Holdings (NYSE: ARX) announced preliminary unaudited financial highlights for both the fourth quarter and year ended December 31, 2025.
Accelerant announces leadership updates
Accelerant (ARX) announced the appointments of Cliff Jenks as General Counsel and Corporate Secretary and Ray Iardella as Head of Investor Relations. Jenks will oversee Accelerant’s legal affairs and ...
Accelerant Announces Leadership Updates Across Legal and Investor Relations
ATLANTA--(BUSINESS WIRE)--Accelerant announces the appointments of Cliff Jenks as General Counsel and Corporate Secretary and Ray Iardella as Head of Investor Relations.
Accelerant price target lowered to $13 from $18 at Piper Sandler
Piper Sandler analyst Paul Newsome lowered the firm’s price target on Accelerant (ARX) to $13 from $18 and keeps an Overweight rating on the shares. The firm is revising its
Accelerant price target lowered to $13 from $21 at Raymond James
Raymond James analyst C. Gregory Peters lowered the firm’s price target on Accelerant (ARX) to $13 from $21 and keeps an Outperform rating on the shares. Insurance brokers and insurance-related
Accelerant Announces Date of Fourth Quarter and Full Year 2025 Financial Results and Conference Call
ATLANTA--(BUSINESS WIRE)--Accelerant Holdings (NYSE: ARX), a leading technology company operating a data-driven risk exchange platform for the specialty insurance market, today announced that it will ...
Accelerant price target raised to $20 from $19.50 at Goldman Sachs
Goldman Sachs analyst Robert Cox raised the firm’s price target on Accelerant (ARX) to $20 from $19.50 and keeps a Buy rating on the shares. In a sector note on
Accelerant price target raised to $18 from $15 at Piper Sandler
Piper Sandler raised the firm’s price target on Accelerant (ARX) to $18 from $15 and keeps an Overweight rating on the shares. The firm still thinks the long-term prospects for
Accelerant Holdings Earnings Call Transcript: Q3 2025
Q3 saw robust growth with exchange-rated premium up 17% (29% adjusted), revenue up 74%, and adjusted EBITDA up over 300%. Strategic expansion of third-party insurer relationships and data capabilities support strong guidance for 2026, with two-thirds of premium expected from third parties.
Accelerant Announces Third Quarter 2025 Results
ATLANTA--(BUSINESS WIRE)--Accelerant Holdings (NYSE: ARX), a leading technology company operating a data-driven risk exchange platform for the specialty insurance market, today announced financial res...